Molecule restores cognition and memory in Alzheimer's disease mouse study

UCLA Health researchers have identified and synthesized a molecule, DDL-920, that shows promise in restoring cognitive functions in mice exhibiting symptoms of Alzheimer’s disease. The study, published in the Proceedings of the National Academy of Sciences, demonstrated that DDL-920 effectively jump-started the brain's memory circuitry, allowing Alzheimer’s model mice to recall escape routes in a maze at rates comparable to healthy mice. Unlike existing FDA-approved Alzheimer’s treatments that primarily focus on removing harmful plaques, DDL-920 aims to enhance gamma oscillations in the brain, which are crucial for memory and cognitive functions. The compound works by antagonizing certain receptors in fast-firing neurons, thereby enabling these neurons to sustain more powerful gamma oscillations. While the results in mice are promising, researchers caution that further studies are necessary to evaluate the safety and efficacy of DDL-920 in humans. If successful, this treatment could also have implications for other conditions associated with diminished gamma oscillations, such as depression and schizophrenia.

- UCLA researchers have developed a molecule, DDL-920, that restores cognitive functions in Alzheimer’s disease model mice.

- DDL-920 enhances gamma oscillations in the brain, which are essential for memory and cognition.

- The compound works differently from existing Alzheimer’s treatments by targeting neuronal circuits rather than just removing plaques.

- Further research is needed to assess the safety and effectiveness of DDL-920 in humans.

- The treatment may also benefit other conditions linked to reduced gamma oscillations, such as depression and autism spectrum disorder.